Founded in 2015, Amiko is growing to become a global provider of hardware enabled, AI powered digital medicines. Amiko’s first product is Respiro, a digital medicine product that upgrades respiratory care using proprietary sensing technology, cognitive computing and elegant digital experiences. Amiko Digital Health Limited develops, designs, and commercializes digital medicines that improve medication adherence, assist health professionals and empower patients to achieve better outcomes. Amiko’s first product is Respiro, a digital medicine offering that optimises respiratory therapies using the world’s most advanced smart inhalers. Respiro is an approved and clinically validated digital medicine product that combines connected inhaler sensors, digital applications, behaviour change programs and predictive analytics to personalize respiratory treatment. Track when and how well patients use their inhalers, and generates personalized inspiration profiles to help monitor disease progression.
Total Funding: N/A
Funding Stage: Funded
Business Stage: Scaling Up
Market: B2C, B2B
Company Size: 1 to 25
Founded: 2015
